Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study

Abstract Denosumab is a human IgG2 monoclonal antibody against receptor activator of nuclear factor kappa‐B ligand (RANKL) for the treatment of osteoporosis and bone loss. HLX14 is a proposed biosimilar of denosumab. This randomized, parallel‐group, two‐part, phase I study aimed to compare the pharm...

Full description

Saved in:
Bibliographic Details
Main Authors: Nanyang Li, Nannan Chu, Leilei Zhu, Xiaojie Wu, Qiong Wei, Jiahui Wang, Xuhui Hu, Haoyu Yu, Qingyu Wang, Wei'an Yuan, Kai Huang, Jing Zhang
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70089
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items